Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2023-03-15 Notice of Dividend Amou…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
[기재정정]주식배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding a 'Stock Dividend Decision' (주식배당결정). It is a correction filing (정정신고) updating the number of shares to be issued as dividends due to changes in total outstanding shares. Since this document specifically details the dividend amount and payment structure for shareholders, it falls under the 'Notice of Dividend Amount' category.
2023-03-15 Korean
[기재정정]주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding a 'free capital increase' (bonus issue/stock split). It is a formal amendment ('정정신고') to a previous filing, detailing changes in the number of shares and capital structure. This falls under the category of share issuance or capital changes.
2023-03-14 Korean
권리락(무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding a 'rights off' (권리락) event due to a bonus issue (무상증자). It provides specific details such as the company name, stock type, reference price, and the effective date. This fits the definition of a capital change announcement related to share issuance/capital structure adjustments.
2023-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Therapeutics. It contains the meeting agenda, date, location, and details regarding voting procedures (electronic voting, proxy). It also includes 'Management Reference Materials' (경영참고사항) which provide business overviews, industry analysis, and board activity reports. This is a standard proxy statement/notice of meeting document sent to shareholders to solicit votes and provide information for the upcoming Annual General Meeting. In the context of the provided categories, this fits best as a Proxy Solicitation & Information Statement.
2023-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with the DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains information about the meeting date, agenda items (such as approval of financial statements), and instructions for electronic voting. While it contains financial data, it is not an Annual Report (10-K) or an Interim Report (IR) itself, but rather a proxy solicitation document used to facilitate the AGM process. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2023-03-07 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a 'Decision on Bonus Issue' (무상증자결정). This document details the issuance of new shares to existing shareholders, which falls under capital structure changes. According to the provided definitions, announcements regarding new share issues or capital changes are classified as 'Share Issue/Capital Change' (SHA).
2023-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.